查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401893

2030年视网膜疾病治疗的全球市场预测：按类型、疾病类型、治疗方法、剂型、给药途径、配销通路、最终用户和地区进行分析

Retinal Disease Therapeutics Market Forecasts to 2030 - Global Analysis By Type, Disorder Type (Genetic and Age Related), Treatment Technique, Dosage Form, Route of Administration, Distribution Channel, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球视网膜疾病治疗市场规模为 139.9 亿美元，预计到 2030 年将达到 296 亿美元，预测期内复合年增长率为 11.3%。

一组称为视网膜疾病的疾病会影响视网膜（眼睛后部的感光组织）。这些疾病会损害视网膜的正常功能，并可能导致失明或视力障碍。此外，视网膜疾病治疗的目标是控制和治疗这些病症，以维持或改善患者的视力。根据特定的疾病及其严重程度，可以使用多种治疗方法，包括药物、雷射疗法、手术和植入装置。

根据世界卫生组织（WHO）发布的《世界视力报告》，全球约有22亿人患有视力障碍，其中约6,000万人失明。

糖尿病盛行率增加

由于饮食和生活方式的改变导致全世界糖尿病患者数量不断增加，视网膜疾病治疗正在经历显着增长。此外，全球糖尿病患者数量的增加与解决糖尿病视网膜併发症的治疗需求的增加直接相关。这是因为糖尿病是糖尿病视网膜病变的主要危险因素，而糖尿病视网膜病变常导致视力丧失。

缺乏治疗依从性

某些视网膜疾病需要持续的、有时是侵入性的治疗。患者因不适、恐惧或其他问题而抵制，可能会导致对此类治疗计划的不一致医嘱遵从性。此外，医嘱遵从性性差会降低治疗性介入的有效性并危及患者的长期结果。提高治疗便利性和解决患者担忧对于提高医嘱遵从性至关重要。

个体化医疗的发展

透过将基因组和分子资料不断整合到临床实践中，可以实现视网膜疾病治疗中的个人化医疗。全面的基因谱和生物标记分析可以开发针对每位患者独特基因组成的标靶治疗。此外，这种旨在最大限度地减少副作用和优化治疗效果的策略可以为精准医学带来重大进步。

负担能力和经济障碍

经济不平等和高昂的治疗费用可能严重阻碍获得视网膜疾病的治疗方法。除了限制患者就医之外，财务不安全也给卫生系统带来压力，并使其难以提供全面的照护。经济衰退和其他景气衰退可能会加剧这些障碍，并危及尖端视网膜治疗的公平分配。

COVID-19 的影响：

视网膜疾病治疗市场受到 COVID-19大流行的严重影响。由于医疗保健系统的中断、疫情应对资源的重新分配以及患者获得常规护理的机会有限，视网膜疾病的诊断和治疗被推迟。暂停的临床试验阻碍了新治疗方法的开发。此外，不断变化的医疗保健优先事项和经济不确定性可能会影响市场动态，并对视网膜疾病的研究经费和治疗方法发展产生长期影响。此次疫情增加了远端医疗解决方案在视网膜疾病治疗中的使用，并凸显了强大的医疗保健系统的重要性。

预计黄斑部病变部分在预测期内将是最大的部分

黄斑部病变领域在视网膜疾病治疗市场中占有最大占有率。在老年人中，黄斑部病变，更具体地说是老龄化黄斑部病变（AMD），是常见的，也是视力丧失的主要原因。此外，全球人口高龄化正在推动该行业的崛起。视网膜的中央部分黄斑部受到 AMD 的影响，导致视力扭曲、模糊，在极端情况下甚至会丧失中央视力。抗 VEGF 药物和其他减缓病情进展的标靶治疗在商业上可用于治疗黄斑部病变。

预测期内，居家医疗领域预估复合年增长率最高

在这个市场中，居家医疗领域正以最高的复合年增长率成长。对以患者为中心的护理的需求、人口高龄化以及允许在家中进行更复杂治疗的技术进步都促进了居家医疗的普及。此外，居家医疗服务包括广泛的医疗和非医疗治疗，例如药物管理、慢性病监测和復健治疗，所有这些都可以在您舒适的家中进行。

占有率最大的地区

预计北美将占据全球视网膜疾病治疗药物市场的最大占有率。该地区人口众多，人口高龄化，更容易患视网膜疾病，医疗基础设施先进，眼科治疗研发生态系统蓬勃发展，这是该地区的主导因素。大型製药公司、学术研究中心和最先进的医疗设施是北美始终保持视网膜疾病治疗行业领导者地位的一些因素。该地区享有的另一个优势是积极的法规环境，鼓励创新并加速新治疗方法的核准流程。

复合年增长率最高的地区：

在视网膜疾病治疗药物市场中，欧洲地区预期复合年增长率最高。该地区的优势包括完善的医疗保健系统、与老龄化相关的视网膜疾病的高发病率以及较早获得最先进治疗的机会。英国、德国和法国等欧洲国家高度重视眼科研究和开发，推动视网膜疾病治疗方法的改进。此外，该地区的显着增长也归功于有利的法律规范以及製药公司和学术机构之间不断增长的合作伙伴关係。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球视网膜疾病治疗药物市场：依类型

  • 介绍
  • 黄斑部病变
  • 糖尿病眼科疾病
  • 视网膜剥离
  • 视网膜母细胞瘤
  • 黄斑皱纹
  • 黄斑裂孔
  • 飞蚊症
  • 其他类型

第六章全球视网膜疾病治疗药物市场：依疾病类型

  • 介绍
  • 遗传上
  • 老龄化

第七章全球视网膜疾病治疗药物市场：依治疗方法分类

  • 介绍
  • 雷射
  • 冷冻的
  • 移植
  • 缩排
  • 气压式融合术
  • 巩膜屈曲
  • 玻璃体切除术

第八章全球视网膜疾病治疗药物市场：按剂型

  • 介绍
  • 凝胶
  • 眼药水
  • 胶囊和锭剂
  • 眼药水
  • 软膏
  • 其他剂型

第九章全球视网膜疾病治疗药物市场：依给药途径给药

  • 介绍
  • 口服
  • 局部的
  • 玻璃体内

第十章全球视网膜疾病治疗药物市场：依配销通路

  • 介绍
  • 医院药房
  • 线上药房
  • 零售药房
  • 直接竞标
  • 其他配销通路

第十一章全球视网膜疾病治疗药物市场：依最终用户分类

  • 介绍
  • 医院
  • 门诊手术中心
  • 居家医疗
  • 其他最终用户

第十二章全球视网膜疾病治疗药物市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第十三章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十四章 公司简介

  • Santen Pharmaceutical Co. Ltd.
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc
  • Bayer AG
  • Regeneron Pharmaceuticals, Inc.
  • Adverum Biotechnologies, Inc.
  • Roche Holding AG
  • Genentech, Inc.
  • Alcon Inc.
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Senju Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc.
  • Allergan plc
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Spark Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Clearside Biomedical, Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
Product Code: SMRC24413

According to Stratistics MRC, the Global Retinal Disease Therapeutics Market is accounted for $13.99 billion in 2023 and is expected to reach $29.60 billion by 2030 growing at a CAGR of 11.3% during the forecast period. A collection of disorders known as retinal diseases impact the retina, the light-sensitive tissue found at the rear of the eye. These illnesses have the potential to impair the retina's normal function, which could result in blindness or visual impairment. Moreover, the goal of therapies for retinal diseases is to control and treat these conditions in order to maintain or enhance a patient's vision. Depending on the exact ailment and its severity, different treatment modalities may be used, such as medication, laser therapy, surgery, and implantable devices.

According to the World Vision Report released by the World Health Organisation (WHO), nearly 2.2 billion people suffer from vision impairment worldwide, of which approximately 60 million people are blind.

Market Dynamics:

Driver:

Expanding diabetes incidence

Retinal disease therapies are seeing significant growth due to the rise in diabetes cases worldwide, which is being caused by dietary and lifestyle modifications. Moreover, the increasing number of diabetes cases globally is directly correlated with an increased demand for therapeutics addressing diabetic retinal complications, as diabetes is a major risk factor for diabetic retinopathy, a condition that frequently results in vision impairment.

Restraint:

Lack of compliance with treatment

Frequent intravitreal injections are one of the ongoing, occasionally invasive treatments required for certain retinal diseases. Inconsistent adherence to these treatment plans may result from patient resistance brought on by discomfort, fear, or other issues. Additionally, poor adherence reduces the efficacy of therapeutic interventions and may jeopardize patients' long-term results. Improving treatment convenience and addressing patient concerns are essential for raising adherence rates.

Opportunity:

Developments in customized medicine

Personalized medicine in retinal disease therapeutics is made possible by the continuous integration of genomic and molecular data into clinical practice. Targeted therapies can be developed according to each patient's unique genetic composition thanks to thorough genetic profiling and biomarker analysis. Furthermore, precision medicine may advance significantly with this strategy, which aims to minimize side effects and optimize treatment efficacy.

Threat:

Affordability and economic barriers

The availability of treatments for retinal diseases may be severely hampered by economic inequality and high treatment expenses. In addition to restricting patient access, financial worries can put pressure on healthcare systems and make it more difficult to provide complete care. Recessions and other economic downturns have the potential to worsen these obstacles and put the fair distribution of cutting-edge retinal treatments in jeopardy.

COVID-19 Impact:

The market for treatments for retinal diseases has been greatly impacted by the COVID-19 pandemic. Diagnosis and treatment of retinal diseases have been delayed due to disruptions in healthcare systems, redirection of resources to pandemic response, and restrictions on patient access to routine care. Interruptions in clinical trials have impeded the development of new treatments. Furthermore, changes in healthcare priorities and economic uncertainty have affected market dynamics, potentially having long-term effects on funding for research and the development of treatments for retinal diseases. The pandemic has increased the use of telemedicine solutions in the treatment of retinal diseases and highlighted the significance of robust healthcare systems.

The Macular Degeneration segment is expected to be the largest during the forecast period

In the market for treatments for retinal diseases, the macular degeneration segment holds the largest share. Among older adults, macular degeneration-more specifically, age-related macular degeneration, or AMD-is a common and primary cause of vision loss. Moreover, the aging population on a global scale is driving the prominence of this segment. The macula, the core portion of the retina, is impacted by AMD, which can cause vision distortion or blurriness and, in extreme situations, central vision loss. Anti-VEGF medications and other targeted treatments meant to impede the advancement of the condition are available on the market for macular degeneration therapeutics.

The Home Healthcare segment is expected to have the highest CAGR during the forecast period

In the market, the Home Healthcare segment is growing at the highest CAGR. The need for patient-centered care, the aging population, and technological advancements that enable more complex treatments to be administered at home have all contributed to the rise in popularity of home healthcare. Additionally, a vast array of medical and non-medical treatments is included in home healthcare services, such as medication administration, chronic condition monitoring, and rehabilitation therapy delivered to patients in the comfort of their own homes.

Region with largest share:

In the global retinal disease therapeutics market, North America is expected to hold the largest share. The region's large and aging population, which makes it vulnerable to retinal diseases, its sophisticated healthcare infrastructure, and a thriving ecosystem of ophthalmic treatment-focused research and development activities all, contribute to its leadership. Major pharmaceutical companies, academic research centers, and cutting-edge healthcare facilities are some of the factors that consistently make North America a leader in the retinal disease therapeutics industry. A proactive regulatory environment that encourages innovation and speeds up the approval process for new treatments is another advantage that the region enjoys.

Region with highest CAGR:

In the market for treatments for retinal diseases, the Europe region is anticipated to have the highest CAGR. Benefits to the area include an established healthcare system, a high rate of age-related retinal diseases, and the early adoption of cutting-edge therapies. The United Kingdom, Germany, and France are among the European nations that place a high priority on ophthalmology research and development, which promotes improvements in the treatments for retinal diseases. Moreover, the notable growth in the region is also attributed to favourable regulatory frameworks and growing partnerships between pharmaceutical companies and academic institutions.

Key players in the market:

Some of the key players in Retinal Disease Therapeutics market include Santen Pharmaceutical Co. Ltd., AbbVie Inc., Johnson & Johnson Services, Inc, Bayer AG, Regeneron Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Roche Holding AG, Genentech, Inc., Alcon Inc., Novartis AG, F. Hoffmann-La Roche AG, Senju Pharmaceutical Co., Ltd. , Bausch Health Companies Inc., Allergan plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Spark Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Clearside Biomedical, Inc. and Kubota Pharmaceutical Holdings Co., Ltd.

Key Developments:

In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company's "Library of Libraries," a collection of synthetic antibody libraries that harnesses innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery.

In July 2023, Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies. Santen has come to an out-licensing agreement with Visiox Pharmaceuticals, Inc. (hereafter Visiox) on the rights to product manufacturing, commercialization, and sales of OMLONTI®, an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

In February 2023, AbbVie and Capsida Biotherapeutics Inc. announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021.

Types Covered:

  • Macular Degeneration
  • Diabetic Eye Disease
  • Retinal Detachment
  • Retinoblastoma
  • Macular Pucker
  • Macular Hole
  • Floaters
  • Other Types

Disorder Types Covered:

  • Genetic
  • Age Related

Treatment Techniques Covered:

  • Laser
  • Freezing
  • Implanting
  • Indenting
  • Pneumatic Retinopexy
  • Scleral Buckling
  • Vitrectomy

Dosage Forms Covered:

  • Gels
  • Eye solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
  • Other Dosage Forms

Route of Administrations Covered:

  • Oral
  • Topical
  • Intravitreal

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Direct Tender
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Retinal Disease Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Macular Degeneration
  • 5.3 Diabetic Eye Disease
  • 5.4 Retinal Detachment
  • 5.5 Retinoblastoma
  • 5.6 Macular Pucker
  • 5.7 Macular Hole
  • 5.8 Floaters
  • 5.9 Other Types

6 Global Retinal Disease Therapeutics Market, By Disorder Type

  • 6.1 Introduction
  • 6.2 Genetic
  • 6.3 Age Related

7 Global Retinal Disease Therapeutics Market, By Treatment Technique

  • 7.1 Introduction
  • 7.2 Laser
  • 7.3 Freezing
  • 7.4 Implanting
  • 7.5 Indenting
  • 7.6 Pneumatic Retinopexy
  • 7.7 Scleral Buckling
  • 7.8 Vitrectomy

8 Global Retinal Disease Therapeutics Market, By Dosage Form

  • 8.1 Introduction
  • 8.2 Gels
  • 8.3 Eye solutions
  • 8.4 Capsules & Tablets
  • 8.5 Eye Drops
  • 8.6 Ointments
  • 8.7 Other Dosage Forms

9 Global Retinal Disease Therapeutics Market, By Route of Administration

  • 9.1 Introduction
  • 9.2 Oral
  • 9.3 Topical
  • 9.4 Intravitreal

10 Global Retinal Disease Therapeutics Market, By Distribution Channel

  • 10.1 Introduction
  • 10.2 Hospital Pharmacy
  • 10.3 Online Pharmacy
  • 10.4 Retail Pharmacy
  • 10.5 Direct Tender
  • 10.6 Other Distribution Channels

11 Global Retinal Disease Therapeutics Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals
  • 11.3 Ambulatory Surgical Centers
  • 11.4 Home Healthcare
  • 11.5 Other End Users

12 Global Retinal Disease Therapeutics Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Santen Pharmaceutical Co. Ltd.
  • 14.2 AbbVie Inc.
  • 14.3 Johnson & Johnson Services, Inc
  • 14.4 Bayer AG
  • 14.5 Regeneron Pharmaceuticals, Inc.
  • 14.6 Adverum Biotechnologies, Inc.
  • 14.7 Roche Holding AG
  • 14.8 Genentech, Inc.
  • 14.9 Alcon Inc.
  • 14.10 Novartis AG
  • 14.11 F. Hoffmann-La Roche AG
  • 14.12 Senju Pharmaceutical Co., Ltd.
  • 14.13 Bausch Health Companies Inc.
  • 14.14 Allergan plc
  • 14.15 Sun Pharmaceutical Industries Ltd.
  • 14.16 Merck & Co., Inc.
  • 14.17 Spark Therapeutics, Inc.
  • 14.18 Teva Pharmaceutical Industries Ltd.
  • 14.19 Clearside Biomedical, Inc.
  • 14.20 Kubota Pharmaceutical Holdings Co., Ltd.

List of Tables

  • Table 1 Global Retinal Disease Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Retinal Disease Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Retinal Disease Therapeutics Market Outlook, By Macular Degeneration (2021-2030) ($MN)
  • Table 4 Global Retinal Disease Therapeutics Market Outlook, By Diabetic Eye Disease (2021-2030) ($MN)
  • Table 5 Global Retinal Disease Therapeutics Market Outlook, By Retinal Detachment (2021-2030) ($MN)
  • Table 6 Global Retinal Disease Therapeutics Market Outlook, By Retinoblastoma (2021-2030) ($MN)
  • Table 7 Global Retinal Disease Therapeutics Market Outlook, By Macular Pucker (2021-2030) ($MN)
  • Table 8 Global Retinal Disease Therapeutics Market Outlook, By Macular Hole (2021-2030) ($MN)
  • Table 9 Global Retinal Disease Therapeutics Market Outlook, By Floaters (2021-2030) ($MN)
  • Table 10 Global Retinal Disease Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 11 Global Retinal Disease Therapeutics Market Outlook, By Disorder Type (2021-2030) ($MN)
  • Table 12 Global Retinal Disease Therapeutics Market Outlook, By Genetic (2021-2030) ($MN)
  • Table 13 Global Retinal Disease Therapeutics Market Outlook, By Age Related (2021-2030) ($MN)
  • Table 14 Global Retinal Disease Therapeutics Market Outlook, By Treatment Technique (2021-2030) ($MN)
  • Table 15 Global Retinal Disease Therapeutics Market Outlook, By Laser (2021-2030) ($MN)
  • Table 16 Global Retinal Disease Therapeutics Market Outlook, By Freezing (2021-2030) ($MN)
  • Table 17 Global Retinal Disease Therapeutics Market Outlook, By Implanting (2021-2030) ($MN)
  • Table 18 Global Retinal Disease Therapeutics Market Outlook, By Indenting (2021-2030) ($MN)
  • Table 19 Global Retinal Disease Therapeutics Market Outlook, By Pneumatic Retinopexy (2021-2030) ($MN)
  • Table 20 Global Retinal Disease Therapeutics Market Outlook, By Scleral Buckling (2021-2030) ($MN)
  • Table 21 Global Retinal Disease Therapeutics Market Outlook, By Vitrectomy (2021-2030) ($MN)
  • Table 22 Global Retinal Disease Therapeutics Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 23 Global Retinal Disease Therapeutics Market Outlook, By Gels (2021-2030) ($MN)
  • Table 24 Global Retinal Disease Therapeutics Market Outlook, By Eye solutions (2021-2030) ($MN)
  • Table 25 Global Retinal Disease Therapeutics Market Outlook, By Capsules & Tablets (2021-2030) ($MN)
  • Table 26 Global Retinal Disease Therapeutics Market Outlook, By Eye Drops (2021-2030) ($MN)
  • Table 27 Global Retinal Disease Therapeutics Market Outlook, By Ointments (2021-2030) ($MN)
  • Table 28 Global Retinal Disease Therapeutics Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 29 Global Retinal Disease Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 30 Global Retinal Disease Therapeutics Market Outlook, By Oral (2021-2030) ($MN)
  • Table 31 Global Retinal Disease Therapeutics Market Outlook, By Topical (2021-2030) ($MN)
  • Table 32 Global Retinal Disease Therapeutics Market Outlook, By Intravitreal (2021-2030) ($MN)
  • Table 33 Global Retinal Disease Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 34 Global Retinal Disease Therapeutics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 35 Global Retinal Disease Therapeutics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 36 Global Retinal Disease Therapeutics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 37 Global Retinal Disease Therapeutics Market Outlook, By Direct Tender (2021-2030) ($MN)
  • Table 38 Global Retinal Disease Therapeutics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 39 Global Retinal Disease Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 40 Global Retinal Disease Therapeutics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 41 Global Retinal Disease Therapeutics Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 42 Global Retinal Disease Therapeutics Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 43 Global Retinal Disease Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.